Development of novel therapies for Huntington's disease: hope and challenge (Q36016932)

11 August 2017

1 reference

title

Development of novel therapies for Huntington's disease: hope and challenge (English)

1 reference

11 August 2017

0 references

1

Zheng-Hong Qin

1 reference

11 August 2017

Jin Wang

2

1 reference

PubMed ID

15663888

11 August 2017

Zhen-Lun Gu

series ordinal

3

1 reference

11 August 2017

1 February 2005

1 reference

Acta Pharmacologica Sinica

11 August 2017

1 reference

11 August 2017

26

1 reference

11 August 2017

129-142

1 reference

11 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1111/j.1745-7254.2005.00520.x

11 August 2017

0 references

cites work

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Therapeutic opportunities in polyglutamine disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

A cell-based screen for drugs to treat Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Specificity of guinea pig liver transglutaminase for amine substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Cytochrome C and caspase-9 expression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Caspase-8 is required for cell death induced by expanded polyglutamine repeats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Interaction of Huntington disease protein with transcriptional activator Sp1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Huntingtin-protein interactions and the pathogenesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

siRNA-mediated gene silencing in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

The Trk family of neurotrophin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Striatal transplantation in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Safety of intrastriatal neurotransplantation for Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Striatal neural grafting improves cortical metabolism in Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Motor and cognitive improvements in patients with Huntington's disease after neural transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Bilateral human fetal striatal transplantation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Delaying the onset of Huntington's in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Serum haloperidol concentration and choreiform movements in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Riluzole in Huntington's disease (HD): an open label study with one year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Risperidone in treatment of choreoathetosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Fetal striatal transplantation in Huntington's disease: time for a pause

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00520.X

10.1111/J.1745-7254.2005.00520.X

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

15663888

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15663888